All In Biotech

Drug Trial Radar · NCT05223920

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

Dec 15, 2021

Primary completion

Aug 22, 2024

Study completion Aug 22, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies').

Conditions

  • Thrombocythemia, Essential
  • Primary Myelofibrosis

Interventions

  • BomedemstatDrug

    Capsule (oral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experience an Adverse Event (AE)Time frame: Up to ~32 months
  2. Percentage of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to ~32 months
  3. Mean Spleen Volume Reduction Based on Spleen Volume Measured by MRI in Participants With MF.Time frame: Baseline and Days 169, 339, 509, 679, 849 and 924
  4. Percentage of Participants With ET Who Achieve a Reduction of Platelet Counts to <= 400 K/uL (400 x 10^9/L) in the Absence of New Thromboembolic EventsTime frame: Baseline and Days 29, 57, 85, 113, 141, 169, 198, 226, 254, 282, 310, 338, 367, 395, 423, 451, 479, 507, 536, 564, 592, 620, and 648

Locations

19 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Miami Leonard M. Miller

    Miami, Florida

  • University of Michigan

    Ann Arbor, Michigan

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • UMPC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Gold Coast Hospital and Health Service

    Southport, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Universittsklinikum Essen

    Essen, Germany

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Azienda Ospedaliera SS. Antonio

    Alessandria, Italy

  • Azienda Ospedaliero-Universitaria Careggi - S.O.D. Ematologia (CRIMM)

    Florence, Italy

  • Azienda Ospedaliero Universitaria di Bologna

    Pavia, Italy

  • Ospedale di Circolo-a Fondazione Macchi

    Varese, VA, Italy

  • Middlemore Clinical Trials

    Papatoetoe, Aukland, New Zealand

  • Waitemata District Health Board

    Takapuna, Aukland, New Zealand

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Guy's and Saint Thomas' NHS Foundation Trus

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.